Dante Labs' CEO Andrea Riposati Is Inspired to Bring Whole Genome Sequencing to Patients

Worldwide

Andrea Riposati has the vision to bring whole genome sequencing to patients worldwide. Whole
genome sequencing is revolutionizing healthcare by allowing us to see an individual's potential
for diseases such as cancer. Many of us are now taking steps towards precision medicine. Thanks
to groundbreaking technological advancements in fast, accurate, and affordable DNA
sequencing, analyzing its data is becoming increasingly routine.

The future of genomics isn't simply about what we can learn about our genomes but about how
the information is used. It's incumbent on us to think seriously about the implications of our
knowledge and what we can do with it. That's why Andrea Riposati was inspired to start a
company called Dante Labs in 2016.

Dante labs' objective is to bring whole genome sequencing to patients worldwide. It's a powerful
vision, and Andrea Riposati has been working towards making it a reality for the past two years.
In 2016, Dante Labs partnered with Sanger, one of the world's leading DNA sequencing
providers. We're now working together on bringing our services to patients in Europe, Africa,
Asia, and the Americas using our first mobile laboratory, the BioViva mobile system.

Whole genome sequencing is a revolutionary technology that can be used for many different
applications. Here on BioViva, we are using it to do personalized therapeutics. This application
of whole genome sequencing aims to learn about your genome, tissues, and cells and then
evaluate how activated or deactivated specific genes are. Genes turned on too much or too little
are candidates for gene editing with innovative solutions such as those pioneered by BioViva,
which were developed at Harvard University.

Whole genome sequencing is another tool that can diagnose diseases and monitor the effects of
treatments ranging from drugs to lifestyle changes. It's only a matter of time before this
methodology is used to notify when a disease appears, and advanced treatments can then be
initiated. This will make whole genome sequencing more available and accessible to become
more standard in medicine.